<DOC>
	<DOCNO>NCT03074864</DOCNO>
	<brief_summary>The aim study investigate efficacy safety intercalate combination erlotinib radiotherapy patient EGFR-mutant , unresectable , locally advanced NSCLC , explore new treatment strategy subset . After Induction erlotinib , local radiotherapy intercalate , follow 24-week erlotinib maintenance .</brief_summary>
	<brief_title>Targeted Treatment With Intercalated Radiotherapy EGFR-mutant IIIA/IIIB NSCLC</brief_title>
	<detailed_description>Chemoradiation therapy standard treatment unresectable , locally advanced NSCLC , efficacy reach platform , treatment-related life threaten toxicity limit use . The EGFR tyrosine kinase inhibitor ( TKIs ) produce dramatic response patient carry EGFR activate mutation metastatic setting . Multiple prospective trial show EGFR-TKIs good tolerability compare chemotherapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Males female age ≥18 year . 2 . ECOG performance status 02 . 3 . Pathologically diagnose nonsmall cell lung cancer , stag unresectable IIIA/IIIB accord TNM staging system ( 2009 ) . 4 . EGFR activate mutation exon 18 , 19 21were detected tumor tissue plasma . 5 . Measurable disease must characterize accord RECIST 1.1 criterion . 6 . Life expectancy ≥12 week . 7 . Adequate pulmonary function : FEV1.0 &gt; 50 % normal predict value , DLCO &gt; 40 % normal predict value . 8 . Adequate liver function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤ 3.0 x ULN subject without liver metastasis ; ≤ 5 x ULN subject liver metastasis . 9 . Adequate renal function : serum creatinine ≤ 1 . 5 x ULN , creatinine clearance ≥ 45 ml/min . 10 . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥1.0 x 109/L , Platelet count ≥75 x 109/L , Hemoglobin ≥8 g/dL . 11 . Female subject pregnant breastfeeding . 12 . Written inform consent provide . 13 . Able comply require protocol followup procedure , able receive oral medication . 1 . Histologically mixed smallcell lung cancer . 2 . Mutations EGFR exon 20 detect . 3 . Exposure prior chest irradiation enrollment . 4 . Patients prior chemotherapy agent direct HER axis ( e.g . erlotinib , gefitinib , cetuximab , trastuzumab ) . 5 . History another malignancy last 5 year exception following : Other malignancy cure surgery alone continuous diseasefree interval 5 year permit ; Cured basal cell carcinoma skin cure situ carcinoma uterine cervix permit . 6 . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . 7 . Existence interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Activating mutation , lung cancer , radiotherapy</keyword>
</DOC>